Explore

Recent news and media from the Citizen Stash squad.

Experion Exhibiting at Upcoming Lift & Co. Cannabis Expo

VANCOUVER, BC / ACCESSWIRE/ January 04, 2019 / Viridium Pacific Group Ltd. (“Viridium” or the “Company”)(VIR.V) (VIRFF) is pleased to announce that Experion BiotechnologiesInc. (“Experion”), a wholly owned subsidiary, will be hosting a booth as an Exhibitorat the Lift & Co Cannabis Expo taking place January 11 to 13, 2019, at the VancouverConvention Center, Left Wing in Vancouver, British Columbia. The Experion team willbe located at Booth 544 in the Main Conference Hall.

The Lift Cannabis Expo is one of the leading cannabis industryevents in Canada. The conference and expo will feature key speakers and exhibitorsfocusing on industry and consumers. Networking opportunities will include growingand cultivation companies, health and wellness, finance, policy and regulations,marketing and branding, research and development, product engineering, patient care,retail distribution, government, legal, and media. As an exhibitor, the trade showwill be an opportunity for Experion to meet shareholders, talk to existing and newinvestors, liaise with industry experts, as well as, exhibit our services and brandsfor the medical, wellness and non-medical retail cannabis market.

About Viridium

Viridium Pacific Group Ltd. is a consumer wellness and biotechinnovation company based in British Columbia, and the parent company of operatingsubsidiaries involved in horticultural production, (Experion Biotechologies Inc.)property development (Fish Trap Ventures Ltd.), and human resource management (StaveLake Services Ltd.) Experion Biotechnologies Inc., is a Health Canada licensed producerof cannabis, which operates in an 8,300 square-foot indoor facility outside of Mission,BC.

More information about Viridium can be found under the Company’sprofile on SEDAR at www.sedar.com.

For further information:

Viridium Pacific GroupLtd.

Renmark Financial CommunicationsInc.
Melanie Barbeau: mbarbeau@renmarkfinancial.com
Tel: (416) 644-2020 or (514) 939-3989
www.renmarkfinancial.com

Disclosure

Thispress release contains forward-looking information within the meaning of Canadiansecurities laws. Although the Company believes that such information is reasonable,it can give no assurance that such expectations will prove to be correct.

Forwardlooking information is typically identified by words such as: believe, expect, anticipate,intend, estimate, forecast, postulate and similar expressions, or are those, which,by their nature, refer to future events. The Company cautions investors that anyforward-looking information provided by the Company are not guarantees of futureresults or performance, and that actual results may differ materially from thosein forward looking information as a result of various factors, including, but notlimited to: the state of the financial markets for the Company’s equity securities;recent market volatility; the Company’s ability to raise the necessary capital orto be fully able to implement its business strategies; the risks identified in theFiling Statement, and other risks and factors that the Company is unaware of atthis time. The reader is referred to the Filing Statement dated September 25, 2017and/or the most recent annual and interim Management’s Discussion and Analysis fora more complete discussion of such risk factors and their potential effects, copiesof which may be accessed through the Company page on SEDAR at www.sedar.com.

SOURCE: Viridium Pacific GroupLtd.

Experion Launches ‘Citizen Stash’ Brand for Canada’s Recreational Cannabis Market

VANCOUVER, BC / ACCESSWIRE/ December 18, 2018 / Viridium Pacific Group Ltd. (“Viridium” or the “Company”)(VIR.V) (VIRFF) is pleased to announce that Experion BiotechnologiesInc. (“Experion”), a wholly owned subsidiary licensed under the Cannabis Act, haslaunched its first adult-use cannabis brand, Citizen Stash. During the O’CannabizConference & Expo, which took place December 9 to 11, 2018 in Vancouver, BritishColumbia, the Citizen Stash brand was introduced. The brand was created to appealto those seeking recreational cannabis in Canada’s recently legalized market.

Citizen Stash cannabis products will be hand cultivated inExperion’s indoor facility in Mission, British Columbia to the highest standardsto ensure quality and exceptional user experience Although Experion has not seta firm launch date, the Company is aiming to market and have available for saleits first Citizen Stash product in the first quarter of 2019.

“Citizen Stash is about coming together. We want Citizen Stashto be a brand that is all about celebrating our collective experience as Canadians.Our efforts with regard to finalizing supply agreements for the recreational marketsin BC and Saskatchewan are progressing well, which means that we are getting excitedabout shipping our first Citizen Stash product,” stated Jay Garnett, Viridium Presidentand Chief Executive Officer. “We will be supporting the launch of Citizen Stashthrough our web and social media efforts, and brand activities and experiences.”

Corporate Note

Further to the Company’s news releaseof March 16, 2018 announcing, amongst other things, the resignation of Steve Serenas,the Company advises that notwithstanding its best efforts, it has been unable tocome to a final understanding with Mr. Serenas on his terminal compensation packageeven though it was agreed to following his resignation. Similarly, upon Chris McArthur’sdeparture from the Company, as announced May 7, 2018, the Company has had ongoingdiscussions with him on his terminal compensation package but no agreement has yetbeen reached.

About Viridium

Viridium Pacific Group Ltd. is a consumer wellness and biotechinnovation company based in British Columbia, and the parent company of operatingsubsidiaries involved in horticultural production, (Experion Biotechologies Inc.)property development (Fish Trap Ventures Ltd.), and human resource management (StaveLake Services Ltd.) Experion Biotechnologies Inc., is a Health Canada licensed producerof cannabis, which operates in an 8,300 square-foot indoor facility outside of Mission,BC.

More information about Viridium can be found under the Company’sprofile on SEDAR at www.sedar.com.

For further information:

Renmark Financial CommunicationsInc.
Melanie Barbeau: mbarbeau@renmarkfinancial.com
Tel: (416) 644-2020 or (514) 939-3989
www.renmarkfinancial.com

Disclosure

Thispress release contains forward-looking information within the meaning of Canadiansecurities laws. Although the Company believes that such information is reasonable,it can give no assurance that such expectations will prove to be correct.

Forwardlooking information is typically identified by words such as: believe, expect, anticipate,intend, estimate, forecast, postulate and similar expressions, or are those, which,by their nature, refer to future events. The Company cautions investors that anyforward-looking information provided by the Company are not guarantees of futureresults or performance, and that actual results may differ materially from thosein forward looking information as a result of various factors, including, but notlimited to: the state of the financial markets for the Company’s equity securities;recent market volatility; the Company’s ability to raise the necessary capital orto be fully able to implement its business strategies; the risks identified in theFiling Statement, and other risks and factors that the Company is unaware of atthis time. The reader is referred to the Filing Statement dated September 25, 2017and/or the most recent annual and interim Management’s Discussion and Analysis fora more complete discussion of such risk factors and their potential effects, copiesof which may be accessed through the Company page on SEDAR at www.sedar.com.

SOURCE: Viridium Pacific GroupLtd.

Viridium Reports Fiscal 2018 Third Quarter Results

VANCOUVER, BC / ACCESSWIRE / October 24, 2018 / Viridium Pacific Group Ltd. (“Viridium” or the “Company”) (VIR.V) (VIRFF) is pleased to announce its financial results for the third quarter of fiscal year 2018. The Company’s third quarter filings, including quarterly financial statements and “Management Discussion & Analysis” are now available on SEDAR (www.sedar.com).

“Our third quarter was a strong push for us ahead of legalization. In achieving our initial sales license, we paved the way for our first commercial transaction following quarter end,” said Jay Garnett, Viridium President and Chief Executive Officer. “With commercial activities underway at Experion, we are building momentum heading into the first phase of the legal cannabis market in Canada.”

Quarterly Business Highlights

  • Viridium engaged Renmark Financial Communications Inc. to represent the Company in the area of investor relations, and Integral Wealth Securities Securities Limited for making a market in the shares of the Company.
  • Health Canada granted an amended license for wholesale distribution of dried cannabis for the medical market to Experion Biotechnologies Inc. (“Experion”), a wholly owned subsidiary of the Company.
  • Experion signed a Memorandum of Understanding (“MOU”) with the British Columbia Liquor Distribution Branch (“BCLDB”), the provincial wholesaler for all adult use cannabis in BC. Also, Experion is in discussions and working with the largest Saskatchewan provincial wholesale distributor for adult use cannabis.
  • Experion announced a partnership with the British Columbia Institute of Technology (“BCIT”) to co-develop proprietary genetics for commercial distribution.
  • Viridium shareholders exercised 2,227,860 warrants generating cash proceeds of $1,994,682 million.

Subsequent Events

  • Viridium entered into a Memorandum of Understanding with Montreal Medical Cannabis Inc. to expand production and distribution activities into the province of Quebec.
  • Experion became revenue positive after completing its first and second sales of dried medical cannabis to wholesale purchasers, announced on October 1, 2018 and October 11, 2018, respectively.
  • Experion received license amendments from Health Canada for the sale of starter material, the extraction and production of cannabis oil, and sales of dried flower directly to medical patients.
  • Viridium proposed a private placement offering of units at a price of $0.91 per unit, consisting of one common share and one warrant (exercisable within 12 months at $1.14 per share), to raise $16 million in gross proceeds.
  • Viridium appointed Jay Garnett as President and Chief Executive Officer.
  • Viridium granted 449,625 options to its director, officer and employees at $0.91 expiring between October 23, 2020 and October 23, 2021 with various vesting terms, as well as 40,913 RSUs at a deemed value of $0.91 to a director vesting immediately.

About Viridium

Viridium Pacific Group Ltd. is a consumer wellness and biotech innovation company based in British Columbia, and the parent company of operating subsidiaries involved in horticultural production, (Experion Biotechologies Inc.) property development (Fish Trap Ventures Ltd.), and human resource management (Stave Lake Services Ltd.) Experion Biotechnologies Inc., is a Health Canada licensed producer of cannabis, which operates in an 8,300 square-foot indoor facility outside of Mission, BC.

More information about Viridium can be found under the Company’s profile on SEDAR at www.sedar.com.

For further information:

Viridium Pacific Group Ltd.

Jarrett Malnarich
Tel: (604) 837-8688
info@viridiumpacific.com
www.viridiumpacific.com

Renmark Financial Communications Inc.

Melanie Barbeau: mbarbeau@renmarkfinancial.com
Tel: (416) 644-2020 or (514) 939-3989
www.renmarkfinancial.com

Disclosure

This press release contains forward-looking information within the meaning of Canadian securities laws. Although the Company believes that such information is reasonable, it can give no assurance that such expectations will prove to be correct.

Forward looking information is typically identified by words such as: believe, expect, anticipate, intend, estimate, forecast, postulate and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking information provided by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward looking information as a result of various factors, including, but not limited to: the state of the financial markets for the Company’s equity securities; recent market volatility; the Company’s ability to raise the necessary capital or to be fully able to implement its business strategies; the risks identified in the Filing Statement, and other risks and factors that the Company is unaware of at this time. The reader is referred to the Filing Statement dated September 25, 2017 and/or the most recent annual and interim Management’s Discussion and Analysis for a more complete discussion of such risk factors and their potential effects, copies of which may be accessed through the Company page on SEDAR at www.sedar.com.

SOURCE: Viridium Pacific Group Ltd.

Viridium Pacific Group Announces C$16 Million Private Placement Financing

VANCOUVER, BC / ACCESSWIRE / October 14, 2018 / Viridium Pacific Group Ltd. (“Viridium” or the “Company”) (VIR.V) (OTC PINK: VIRFF) is proposing a common equity financing by way of a private placement of 17,582,418 units (the “Units”) at a price of $0.91 per Unit (the “Offering Price”) to raise aggregate gross proceeds to the Company of $16,000,000 Canadian dollars (the “Offering”).

Under the terms of the financing, each Unit is comprised of one common share of the Company (a “Common Share”) and one non-transferable Common Share purchase warrant (each whole Common Share purchase warrant, a “Warrant”). Each Warrant entitles the holder to acquire one Common Share (a “Warrant Share”) for a period of 12 months following the closing of the Offering (the “Closing”) at an exercise price of $1.14 per Warrant Share.

The securities issued pursuant to the private placement will be subject to a standard 120 day hold period from the Closing. The Company may pay a 7% finders’ fee in cash and 7% finder’s warrants to purchase Common Shares of the Company for 12 months at $0.91 in connection with the private placement, subject to compliance with the policies of the Exchange. Completion of the private placement and the payment of any finders’ fee remain subject to the receipt of all necessary regulatory approvals, including the approval of the Exchange.

The net proceeds of the private placement will be used for the construction of the proposed 87,120 square feet growing facility, general working capital, and closing costs.

About Viridium

Viridium Pacific Group Ltd. is a consumer wellness and biotech innovation company based in British Columbia, and the parent company of operating subsidiaries involved in the horticultural production, (Experion Biotechologies Inc.) property development (Fish Trap Ventures Ltd.), and human resource management (Stave Lake Services Ltd.) Experion Biotechnologies Inc. is a Health Canada licensed producer of cannabis, which operates in an 8,300 square-foot indoor facility outside of Mission, BC.

More information about Viridium can be found under the Company’s profile on SEDAR at www.sedar.com.

For further information:

Viridium Pacific Group Ltd.

Jarrett Malnarich
Tel: (604) 837-8688
info@viridiumpacific.com
www.viridiumpacific.com

Renmark Financial Communications Inc.

Melanie Barbeau: mbarbeau@renmarkfinancial.com
Tel: (416) 644-2020 or (514) 939-3989
www.renmarkfinancial.com

Disclosure

This press release contains forward-looking information within the meaning of Canadian securities laws. Although the Company believes that such information is reasonable, it can give no assurance that such expectations will prove to be correct.

Forward-looking information is typically identified by words such as: believe, expect, anticipate, intend, estimate, forecast, postulate and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking information provided by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward-looking information as a result of various factors, including, but not limited to: the state of the financial markets for the Company’s equity securities; recent market volatility; the Company’s ability to raise the necessary capital or to be fully able to implement its business strategies; the risks identified in the Filing Statement, and other risks and factors that the Company is unaware of at this time. The reader is referred to the Filing Statement dated September 25, 2017 and/or the most recent annual and interim Management’s Discussion and Analysis for a more complete discussion of such risk factors and their potential effects, copies of which may be accessed through the Company page on SEDAR at www.sedar.com.

SOURCE: Viridium Pacific Group Ltd.

Viridium Retains Renmark Financial Communications Inc. for IR and Integral Wealth Securities Limited for Market Marking

August 1, 2018 — Viridium Pacific Group Ltd. (“Viridium” or the “Company”) (TSXV: VIR) (OTCPink: MRRBF) is pleased to announce that it has retained the services of Renmark Financial Communications Inc. (“Renmark”) to handle its investor relations activities.

“We are pleased to have selected Renmark to reinforce Viridium’s profile in the financial community and enhance the visibility of our company. We partnered with Renmark because their standards and methodologies fit best with the message we wish to communicate to the investing public,” noted Jarrett Malnarick, Chief Executive Officer.

For the services to be provided, the monthly fees incurred by Viridium will be a cash consideration of $7,000, starting August 1, 2018 for a period of six months ending on January 31, 2019 and monthly thereafter. Renmark does not have any interest, directly or indirectly, in Viridium or its securities, or any right or intent to acquire such an interest.

Viridium is also pleased to announce that it has retained Integral Wealth Securities Limited (“Integral”) to provide Market-Making services in accordance with TSX Venture Exchange (“TSXV”) policies. Integral will trade securities of Viridium on the TSXV for the purposes of maintaining an orderly market of Viridium’s securities.

In consideration of the services provided by Integral, Viridium will pay Integral a monthly cash fee of $7,000 for a minimum of 12 months with a one-time right to terminate after 6 months, and monthly thereafter. Integral will not receive shares or options as compensation. However, Integral and its clients may have or may acquire a direct interest in the securities of Viridium. Viridium and Integral are unrelated and unaffiliated entities; Integral is a member of the Investment Industry Regulatory Organization of Canada (“IIROC”) and can access all Canadian Stock Exchange and Alternative Trading Systems.

About Viridium

Viridium Pacific Group Ltd. is a consumer wellness and biotech innovation company based in British Columbia, and the parent company of operating subsidiaries involved in horticultural production, (Experion Biotechologies Inc.) property development (Fish Trap Ventures Ltd.), and human resource management (Stave Lake Services Ltd.) Experion Biotechnologies Inc., is a Health Canada licensed producer of cannabis, which operates in an 8,300 square-foot indoor facility outside of Mission, BC.

More information about Viridium can be found under the Company’s profile on SEDAR at www.sedar.com.

Disclosure

This press release contains forward-looking information within the meaning of Canadian securities laws. Although the Company believes that such information is reasonable, it can give no assurance that such expectations will prove to be correct.

Forward looking information is typically identified by words such as: believe, expect, anticipate, intend, estimate, forecast, postulate and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking information provided by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward looking information as a result of various factors, including, but not limited to: the state of the financial markets for the Company’s equity securities; recent market volatility; the Company’s ability to raise the necessary capital or to be fully able to implement its business strategies; the risks identified in the Filing Statement, and other risks and factors that the Company is unaware of at this time. The reader is referred to the Filing Statement dated September 25, 2017 and/or the most recent annual and interim Management’s Discussion and Analysis for a more complete discussion of such risk factors and their potential effects, copies of which may be accessed through the Company page on SEDAR at www.sedar.com.

Viridium Pacific Signs Research Agreement with British Columbia Institute of Technology

July 31, 2018 — Viridium Pacific Group Ltd. (“Viridium” or the “Company”) (TSXV: VIR) (OTCPink: MRRBF) is pleased to announce the signing of a research and development Industry Service Agreement (“ISA”) with the British Columbia Institute of Technology (BCIT).

The research and development ISA is a collaboration between Viridium and its wholly-owned subsidiary Experion Biotechnologies Inc. (“Experion”), a licensed producer under the ACMPR) and BCIT’s Natural Health & Food Products Research Group which hold a controlled substance dealer’s License.  Under the terms of the agreement BCIT will supply specific phenotypic medical cannabis chemovars to Experion for cultivation and harvesting in support of BCIT’s research program. Experion will have exclusive rights to the genetic outcomes of BCIT’s work to be commercialized for the medical and recreational markets. BCIT and Experion will share the benefits of these commercialization efforts as royalty agreement.

Mr. Jarrett Malnarick, CEO commented, “Diversity and scientific knowledge of your genetics are key for any License Producer to succeed in the cannabis industry. Not only does this agreement open up a new channel for genetics development, but also enhances Experion’s expertise concerning cannabis strains and their respective applications and potential.”

About Viridium

Viridium Pacific Group Ltd. is a biotech innovation company based in British Columbia, and the parent company of operating subsidiaries involved in horticultural production (Experion Biotechnologies), property development (Fish Trap Ventures Ltd.), and human resource management (Stave Lake Services Ltd.). Experion Biotechnologies Inc. is a Health Canada licensed producer of cannabis, which operates in an 8,300 square-foot indoor facility outside of Mission, BC.

More information about Viridium can be found under the Company’s profile on SEDAR at www.sedar.com.

Disclosure

This press release contains forward-looking information within the meaning of Canadian securities laws. Although the Company believes that such information is reasonable, it can give no assurance that such expectations will prove to be correct.

Forward looking information is typically identified by words such as: believe, expect, anticipate, intend, estimate, forecast, postulate and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking information provided by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward looking information as a result of various factors, including, but not limited to: the state of the financial markets for the Company’s equity securities; recent market volatility; the Company’s ability to raise the necessary capital or to be fully able to implement its business strategies; the risks identified in the Filing Statement, and other risks and factors that the Company is unaware of at this time. The reader is referred to the Filing Statement dated September 25, 2017 and/or the most recent annual and interim Management’s Discussion and Analysis for a more complete discussion of such risk factors and their potential effects, copies of which may be accessed through the Company page on SEDAR at www.sedar.com.

Stand for Something

Subscribe to our newsletter for updates
and curated content delivered to: